Galapagos NV [GLPGA] vs Pharming Group N.V [PHARM] Detailed Stock Comparison

Galapagos NV

Euronext
Loading...

Pharming Group N.V

Euronext
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Galapagos NV wins in 8 metrics, Pharming Group N.V wins in 10 metrics, with 0 ties. Pharming Group N.V appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricGalapagos NVPharming Group N.VBetter
P/E Ratio (TTM)51.7157.15Galapagos NV
Price-to-Book Ratio0.723.45Galapagos NV
Debt-to-Equity Ratio0.3253.57Galapagos NV
PEG Ratio-41.14-120.60Pharming Group N.V
EV/EBITDA4.2431.79Galapagos NV
Profit Margin (TTM)-103.14%-2.41%Pharming Group N.V
Operating Margin (TTM)-87.35%3.27%Pharming Group N.V
EBITDA Margin (TTM)N/A3.27%N/A
Return on Equity-10.39%-3.70%Pharming Group N.V
Return on Assets (TTM)-5.11%2.85%Pharming Group N.V
Free Cash Flow (TTM)$-402.14M$-2.21MPharming Group N.V
1-Year Return8.41%61.54%Pharming Group N.V
Price-to-Sales Ratio (TTM)6.892.46Pharming Group N.V
Enterprise Value$-1.19B$714.48MPharming Group N.V
EV/Revenue Ratio-4.302.47Galapagos NV
Gross Profit Margin (TTM)92.79%90.38%Galapagos NV
Revenue per Share (TTM)$4$1Galapagos NV
Earnings per Share (Diluted)$-4.38$-0.01Pharming Group N.V
Beta (Stock Volatility)0.030.59Galapagos NV
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Galapagos NV vs Pharming Group N.V Stock Performance Analysis

Loading Price Chart...

Galapagos NV
Pharming Group N.V
Galapagos NV Stock Overview | Pharming Group N.V Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Galapagos NV-0.49%6.63%4.61%22.62%19.05%4.22%
Pharming Group N.V0.80%4.13%7.69%40.00%57.50%31.25%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Galapagos NV8.41%-34.84%-76.41%-21.74%490.10%201.58%
Pharming Group N.V61.54%17.76%35.48%404.00%-31.15%-96.52%

News Based Sentiment: Galapagos NV vs Pharming Group N.V

Galapagos NV

News based Sentiment: MIXED

September was a month of conflicting news for Galapagos NV. While positive clinical trial data and an analyst upgrade boosted sentiment, lowered price forecasts and institutional selling created headwinds. This mixed picture makes it a significant month for understanding the company's trajectory, but doesn't definitively shift the long-term investment case.

View Galapagos NV News Sentiment Analysis

Pharming Group N.V

News based Sentiment: POSITIVE

Pharming Group experienced a highly positive month, marked by a significant earnings beat, promotion to the AMX index, and favorable analyst revisions. These events collectively demonstrate strong company performance and increasing investor confidence, positioning the company for continued growth and making it a compelling investment opportunity.

View Pharming Group N.V News Sentiment Analysis

Performance & Financial Health Analysis: Galapagos NV vs Pharming Group N.V

MetricGLPGAPHARM
Market Information
Market Cap i€1.89B€841.30M
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i66,38614,697,696
90 Day Avg. Volume i70,70115,969,065
Last Close€28.62€1.26
52 Week Range€20.00 - €31.08€0.66 - €1.32
% from 52W High-7.92%-4.32%
All-Time High€252.90 (Feb 17, 2020)€459.55 (Jul 10, 2000)
% from All-Time High-88.68%-99.73%
Growth Metrics
Quarterly Revenue Growth-0.16%0.26%
Quarterly Earnings Growth-0.16%0.07%
Financial Health
Profit Margin (TTM) i-1.03%-0.02%
Operating Margin (TTM) i-0.87%0.03%
Return on Equity (TTM) i-0.10%-0.04%
Debt to Equity (MRQ) i0.3253.57
Cash & Liquidity
Book Value per Share (MRQ)€40.12€0.35
Cash per Share (MRQ)€46.91€0.18
Operating Cash Flow (TTM) i€-278,547,008€26.47M
Levered Free Cash Flow (TTM) i€-33,690,752€19.76M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Galapagos NV vs Pharming Group N.V

MetricGLPGAPHARM
Price Ratios
P/E Ratio (TTM) i51.7157.15
Forward P/E i-41.14-120.60
PEG Ratio i-41.14-120.60
Price to Sales (TTM) i6.892.46
Price to Book (MRQ) i0.723.45
Market Capitalization
Market Capitalization i€1.89B€841.30M
Enterprise Value i€-1,185,225,344€714.48M
Enterprise Value Metrics
Enterprise to Revenue i-4.302.47
Enterprise to EBITDA i4.2431.79
Risk & Other Metrics
Beta i0.030.59
Book Value per Share (MRQ) i€40.12€0.35

Financial Statements Comparison: Galapagos NV vs Pharming Group N.V

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)GLPGAPHARM
Revenue/Sales i€65.29M€79.37M
Cost of Goods Sold i€4.71M€7.64M
Gross Profit i€60.58M€71.73M
Research & Development i€95.28M€20.17M
Operating Income (EBIT) i€-57.03M€7.66M
EBITDA i€-44.29M€8.33M
Pre-Tax Income i€-104.42M€6.03M
Income Tax i€26,000€2.15M
Net Income (Profit) i€-105.75M€3.87M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)GLPGAPHARM
Cash & Equivalents i€108.07M€78.48M
Total Current Assets i€3.47B€209.45M
Total Current Liabilities i€437.04M€74.94M
Long-Term Debt i€7.79M€101.21M
Total Shareholders Equity i€2.75B€204.15M
Retained Earnings i€-280.81M€-243.76M
Property, Plant & Equipment iN/A€20.94M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)GLPGAPHARM
Operating Cash Flow i€-42.99M€10.18M
Capital Expenditures i€-5.10MN/A
Free Cash Flow i€-43.86M€9.90M
Debt Repayment i€-1.01M€-908,445
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLPGAPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i66,38614,697,696
Average Daily Volume (90 Day) i70,70115,969,065
Shares Outstanding i65.90M579.90M
Float Shares i49.17M670.71M
% Held by Insiders i0.25%0.04%
% Held by Institutions i0.32%0.14%

Dividend Analysis & Yield Comparison: Galapagos NV vs Pharming Group N.V

MetricGLPGAPHARM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A